ARIA, Iclusig launch is tracking above expectations to beat Q2 with potential for EGFR data at ESMO (expectations are rightfully low here given too short of follow-up time on first tumor scan) and 1st line EPIC data in Q3:14. Either EGFR responses or clean safety/efficacy in EPIC could significantly improve ARIA takeout prospects since the company is unencumbered by any partnerships
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.